Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02262533 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
A Phase 1 study of N/A - Healthy Subjects, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02262533 is a Phase 1 study of N/A - Healthy Subjects that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02262533, a Phase 1 study of N/A - Healthy Subjects, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
Conditions Studied
Interventions
- DRUG Apixaban
- DRUG Atenolol
Study Locations (1)
New Jersey
- Bms Clinical Research Center - Hamilton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02262533
The ClinicalTrials.gov registry entry for NCT02262533 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with N/A - Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which Apixaban is the first listed.
NCT02262533 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT02262533 about?
NCT02262533 is a clinical study titled "Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects". The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
What is the current status of trial NCT02262533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2007-06. Estimated completion is 2007-06.
What conditions does trial NCT02262533 study?
This clinical trial studies the following conditions: N/A - Healthy Subjects.
What interventions are being tested in trial NCT02262533?
The interventions under investigation include: Apixaban (DRUG), Atenolol (DRUG).
Who is sponsoring clinical trial NCT02262533?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02262533 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for N/A - Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.